Aktis Oncology

Company snapshot

Aktis Oncology (Nasdaq: AKTS) is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company has developed a proprietary miniprotein radioconjugate platform designed to selectively deliver the tumor-killing properties of radioisotopes to

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Aktis Oncology. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Aktis Oncology.

1. May 23, 2026 Clinical update

   [225Ac]Ac-AKY-1189 (therapeutic) — Phase 1

2. May 23, 2026 Clinical update

   [225Ac]Ac-AKY-2519 (therapeutic) — Phase 1

3. Sep 30, 2025 Patent grant

   Nectin-4 binding miniproteins, conjugates and uses thereof

View all clinical trial activity →

• What is Aktis Oncology?

  Aktis Oncology is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AKTS. Primary therapeutic focus areas include Urothelial Carcinoma Bladder, Castration Resistant Metastatic Prostate Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug

• Is Aktis Oncology publicly traded?

  Yes. Aktis Oncology is listed with ticker AKTS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aktis Oncology develop or market?

  No drug profiles are currently linked to Aktis Oncology. Pipeline programs may still list investigational assets.

• What are the latest developments for Aktis Oncology?

  In the last 12 months our linked public records show 2 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Aktis Oncology focus on?

  Aktis Oncology focuses on Urothelial Carcinoma Bladder, Castration Resistant Metastatic Prostate Cancer based on our analysis of their pipeline programs and drug development activities.